Checking out iTransor Lite for offloading WeChat messages. https://t.co/7tvlvNNmIy

8:33am September 3rd 2019 via Twitter Web Client

Here's a video about Safe-SEQ, a new NGS-based technology for highly sensitive liquid biopsy for clinical translati… https://t.co/srGJOk8ZVi

11:16am June 25th 2019 via Twitter Web Client

Are you a diagnostic sales management professional? There may be a place for you at Sysmex Inostics - take a look!… https://t.co/YBqbWECfRH

6:42am June 21st 2019 via Twitter Web Client

@AlbertVilella @jdidion Whoops - missed that! Thanks for pointing it out, profile corrected now.

8:19pm May 28th 2019 via Twitter Web Client in reply to AlbertVilella

@AlbertVilella @jdidion Hey Albert and John - yes only the fourth week in the new role, and lots and lots of things… https://t.co/OKaZyNxwr6

10:19am May 28th 2019 via Twitter Web Client in reply to AlbertVilella

If you didn't think you could trust an NGS clinical test for ctDNA below 1% MAF, take a look at this - from Sysmex… https://t.co/xIyLcM5kOS

10:02am May 28th 2019 via Twitter Web Client

If you didn't think you could trust an NGS clinical test for ctDNA below 1% MAF, take a look at this - from Sysmex… https://t.co/HIcat7Qvy7

7:25am May 28th 2019 via Twitter Web Client

Q: Number of droplets in the technology? Upper limit for GEC? Lipson: #oncobeam #genomewebinar Defers to Sysmex; c… https://t.co/p0Xk9JdQml

12:01pm May 8th 2019 via Twitter Web Client

Q: Hemolytic samples with BEAMing? Holdenrieder: #oncobeam #genomewebinar Preanalytics important; normal EDTA blood… https://t.co/6gCMHfF3Mx

11:58am May 8th 2019 via Twitter Web Client

Q: For clinical work? Lipson: #oncobeam #genomewebinar Impt - what is clinically important? BRAF in melanoma import… https://t.co/T7Q1PpTgKb

11:57am May 8th 2019 via Twitter Web Client

Q: How does BEAMing compare to ddPCR? Holdenrieder: #oncobeam #genomewebinar Different as quality, different as num… https://t.co/IymwZ4D8qc

11:55am May 8th 2019 via Twitter Web Client

Q: How many muts can be measured with the tech? Holdenrieder: #oncobeam #genomewebinar They tested for 5, for BRAF/NRAS measures 7.

11:53am May 8th 2019 via Twitter Web Client

Q: Do you thus incorporate ctDNA into practice? Lipson: #oncobeam #genomewebinar Useful in a few ways; standard, pt… https://t.co/0Ppm1d4WN7

11:52am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Important - what CNAPS structure, biology and function.

11:48am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Summarizing - KRAS correlation 'was good but could be better', KRAS prognost… https://t.co/d123xotaFY

11:48am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Early kinetics: after the first day of Rx, increased considerably. then sha… https://t.co/RPRBsJTS5S

11:46am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Shows chart of sens for det of progressive disease, ctDNA reached 83% in de… https://t.co/p06N32OpVx

11:44am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Found mut in tissue not prognostic, but mut in plasma was. Compared to 3 pr… https://t.co/Sg5oXsYLHK

11:41am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Total 32 muts found in tissue (58%), 36 in plasma. Very high concordance: 7… https://t.co/LjUnLBHy0N

11:40am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Did pyroseq for tissue, BEAMing with plasma. Shows typical results of measu… https://t.co/67xwIcmFBY

11:38am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Asks: do plasma and tissue correlate? Prognostic for pt outcome (OS and PFS… https://t.co/Ja8cY8uNmS

11:37am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar 54 pts with adv panc ca; first-line gemcitabine-based chemo. Tissue + Plasm… https://t.co/uOLcDz7s18

11:36am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Shows chart of freq of KRAS, tp53 mutations in panc cancer. Points to prosp… https://t.co/V3BUkK1SgV

11:35am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar In Pancreatic cancer - not as frequent but high mortality. Often detected l… https://t.co/NFwMgKF5VA

11:34am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar If the mut load is needed, you need to 'go quantitative'. Nice (long!) list… https://t.co/Kj5y37pvBS

11:33am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar BEAMing has high concordance - four references where concordance >90%. Indi… https://t.co/Hc6R315

11:32am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Shows Bettegowda et al figure of percent of cancer types that have detectab… https://t.co/8VfdiVxY1Y

11:31am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Describes liquid biopsy as 'liquid profiling' - as it is looking at markers… https://t.co/etr6P5HMJu

11:30am May 8th 2019 via Twitter Web Client

Holdenrieder: #oncobeam #genomewebinar Nice review of markers by tumor tpe, and description of tumor heterogeneity… https://t.co/BthwRQ4b7F

11:29am May 8th 2019 via Twitter Web Client

Stefan Holdenrieder (Technical University of Munich) OncoBEAM for ctDNA in monitoring of pancreatic cancer. Starts… https://t.co/5ViaGfin74

11:28am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Concl: ctDNA useful melanoma biomarker.

11:27am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Shows example of 68yo female on pembro for met melanoma baseline 0.95% ctDNA, 1.5c… https://t.co/y2Np7TZ9Cr

11:25am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Shows timeline of EDA in circulation prior to imaging in 4 pts. Ave 24 weeks before detection via imaging.

11:23am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar 4/8 pts PD coincident of EDA in ctDNA; other 4 predicted radiographic progression… https://t.co/t3c5PPGzjt

11:22am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Cohort C: n=36, 30 evaluable. All treated, charted mut status, collected serial ct… https://t.co/ff5rHYotd4

11:21am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Cohort B: n=31, 29 evaluable. Recurrent w/1 of 6 hotspot muts: Locoregoinal spread… https://t.co/XJH3Wt46cs

11:19am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Cohort A concl: of 57 pt, 35mm ideal cutoff, two pts unmeasured BRAF in tissue but… https://t.co/0aL0C7YA6M

11:17am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar One pt no BRAF mut in tissue; another insuff quality: both ctDNA revealed bRAF; bo… https://t.co/0xQR3XTtOE

11:16am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Shows burden of 9 pts w/smaller tumors and location - visceral, lung etc. Chart fr… https://t.co/g9gjv4LeIP

11:15am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Of the five + in tumor but neg in ctDNA: low tumor burden (small size). ROC of coh… https://t.co/qFKaeGoUno

11:14am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar 61 pts of cohort A: BRAF 26; NRAS 11; WT 20; N/A: 4. Shows chart of 32/33 pos in… https://t.co/JbAnzxoRlb

11:13am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar 3 cohorts: A single blood draw of met melanoma; B high-risk resected melanoma, ser… https://t.co/f9FdihHLh2

11:11am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Aims - est concordance, est clinical LoD. Single-center study at Hopkins; looked a… https://t.co/M4zAOCArOp

11:10am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Also shows pt after tumor needle biopsy, shows ctDNA level spiking after the biops… https://t.co/UJ6ioysdNt

11:08am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Shows increasing levels of ctDNA correlate w/radiographic disease progression. GEC… https://t.co/M3yOpHOAfS

11:06am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Only two mutations (BRAF and NRAS) represent 50% and 30% of recurrence in melanoma… https://t.co/yW2LQvHRkL

11:05am May 8th 2019 via Twitter Web Client

Lipson: #oncobeam #genomewebinar Starts with a patient stroy - primary, regional recurrence, and distant mets. LDH… https://t.co/4KrjgVxcyo

11:04am May 8th 2019 via Twitter Web Client

Evan Lipson (Johns Hopkins Kimmel CC) Liquid monitoring - optimizing melanoma detection using ctDNA #oncobeam #genomewebinar

11:02am May 8th 2019 via Twitter Web Client

Evan Lipson (Johns Hopkins Kimmel CC) and Stefan Holdenrieder (Technical University of Munich) presenting an… https://t.co/Kui6oM2MKx

11:00am May 8th 2019 via Twitter Web Client

Live Webinar Wed May 8 11am ET OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Mel… https://t.co/CwXVUjZmuq

10:39am May 8th 2019 via Twitter Web Client